Cytel is partnering with LIDE Biotech to conduct a series of webinars, which explores the use of co-clinical trials in expediting drug development for cancer patients. In co-clinical trials, the preclinical studies using functional diagnostic testing and clinical trials will be conducted simultaneously, enabling real-time data integration to accurately stratify and customize treatment for patients individually. MiniPDX, a new technology developed by Shanghai LIDE Biotech, offers a faster alternative to PDX, without losing predictive power for drug response.
The first webinar LIDE President and CEO Dr Danyi Wen will discuss its pros and cons, role in personalized oncology, and use for patient stratification in early clinical trials.
The first webinar in the series looks to draw the following key learnings:
- MiniPDX, in vivo version of organoid assay, overcomes the hurdles of long duration of PDX and the limitation of in vitro dosing (CRC and Organoid). This could be an effective way of patient stratification in early stage of clinical trial.
- MiniPDX + Omics are playing important roles in personalized oncology, as omics analysis enables the identification of biomarkers through advanced bioinformatics analysis.
- IO-FIVE (Immuno-Oncology Fast In Vivo Efficacy test), as the IO version of MiniPDX, can be used as companion diagnosis for patient stratification.
